Clinical trial Recruiting at 2 sites Observational Ages 30 to 90

REMS testing for osteoporosis diagnosis and fracture risk in adults compared with DXA

Official title: Estimation of the Effectiveness of Radiofrequency Echographic Multi Spectrometry (REMS) for the Diagnosis of Osteoporosis and Fracture Risk Prediction in the United States in Comparison With Dual-Energy X-Ray Absorptiometry (DXA)

Run by BoneVue Diagnostics · NCT07876882 · Data updated 2026-11-12

This study tests whether REMS can diagnose osteoporosis and predict fracture risk in adults who are being evaluated for bone health, using DXA as the standard reference.

Quick facts

Study typeObservational
Ages30 Years to 90 Years
SexAll
Enrollment250 (estimated)
SponsorBoneVue Diagnostics
Academic / other
Locations2 sites (Easton, Maryland and 1 other locations)
StatusRecruiting
StartedJune 24, 2026
Main results expectedDecember 24, 2027
Study endsDecember 24, 2027
Registry record updatedOctober 15, 2026
Trial IDNCT07876882 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults ages 30–90 undergoing bone-health evaluation who have had a clinically ordered DXA within the prior seven days and can complete follow-up calls.

Probably not a fit

Individuals not expected to benefit include those with conditions or factors that preclude reliable REMS examination or study follow-up, or those who have not had a recent DXA.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study compares Radiofrequency Echographic Multi Spectrometry (REMS) to dual-energy X-ray absorptiometry (DXA) for diagnosing osteoporosis and predicting fragility fractures. Enrolling about 250 men and women aged 30–90 undergoing bone-health evaluation, all participants will have a prior DXA and will receive a REMS assessment of the lumbar spine and proximal femur. Diagnostic performance will be analyzed in terms of sensitivity, specificity, predictive values, and concordance with DXA. Participants will be followed by telephone at 6 and 12 months to identify incident non-traumatic fragility fractures and to assess how well REMS and DXA predict fracture risk.

Why it matters

Potential benefit: If successful, REMS could provide an alternative or complementary method for osteoporosis diagnosis and fracture risk prediction alongside DXA.

How similar studies have gone: Prior studies have explored REMS in bone health with promising diagnostic concordance to DXA, but broader validation remains ongoing.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 30-90 years at time of enrollment
* Presenting for evaluation of bone health or osteoporosis risk assessment
* Has undergone a clinically ordered DXA scan (lumbar spine, proximal femur) as part of routine medical care through the subject's healthcare provider within the seven days immediately preceding the REMS examination
* Willing and able to provide written informed consent
* Able to comply with study procedures, including telephone follow-up interviews at 6- and 12-months post-enrollment

Exclusion Criteria:

* Inability to provide written informed consent
* Inability to complete an adequate REMS examination
* Declared pregnancy as collected per standard of care prior to DXA

Where it's running

  • Rheumatology Associates of Delmarva
    Easton, Maryland, United States
    Recruiting
  • Rheumatology Associates of Delmarva
    Salisbury, Maryland, United States
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.